Accord Logo

Intended for UK patients and members of the public

PIL - Mometasone Furoate 1mg/g Ointment: Change history

Back to products
  • View Patient Information Leaflet (PIL - Mometasone Furoate 1mg/g Ointment)

    Last updated on this site: 10 Apr 2026

    To update the address of the registered finished product manufacturer, batch release site, QC testing site and primary and secondary packaging site, Tiofarma B.V. from Benjamin Franklinstraat 5-10, 3261 LW Oud-Beijerland, The Netherlands to Hermanus Boerhaavestraat 1, 3261 ME Oud-Beijerland, The Netherlands. The PIL has been updated accordingly.

    View change history

    • Changes: (Updated: 10 Apr 2026)

      To update the address of the registered finished product manufacturer, batch release site, QC testing site and primary and secondary packaging site, Tiofarma B.V. from Benjamin Franklinstraat 5-10, 3261 LW Oud-Beijerland, The Netherlands to Hermanus Boerhaavestraat 1, 3261 ME Oud-Beijerland, The Netherlands. The PIL has been updated accordingly.

    • Changes: (Updated: 10 Mar 2025)

      IAIN, C.I.3.a - To update section 4.8 of the SmPC in line with the MHRA request SA 19259594 for topical mometasone and ADR rosacea. Consequently, the PIL has been updated.

      PIL sections updated: 4 and 6.

    • Changes: (Updated: 05 Sep 2024)

      To update sections 4.4 of the SPC to bring in line with the MHRA request to update potency labelling of topical corticosteroids. Consequentially, the leaflet (PIL) and labelling are updated.

    • Changes: (Updated: 06 Dec 2023)

      Description of update: To update sections 4.4 and 5.1 of the SmPC and the PIL in line with MHRA letter to include the topical corticosteroid potency as defined by the ATC code. Additionally, minor amends have been made to the PIL to correct spelling and grammar.

      PIL sections updated: 1, 2, 3, 4 and 6.

    • Changes: (Updated: 21 Sep 2022)

      Initial upload

    Back to Top

    View product information as a: